{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:30Z","timestamp":1761895890429,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.clml.2014.04.002","type":"journal-article","created":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T14:52:55Z","timestamp":1402498375000},"page":"e165-e168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatic Extramedullary Disease in Multiple Myeloma With 17p Deletion"],"prefix":"10.1016","volume":"14","author":[{"given":"Mikiko","family":"Ise","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tsujimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoya","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.04.002_bib1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.leukres.2009.01.036","article-title":"Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?","volume":"33","author":"Katodritou","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2014.04.002_bib2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of\u00a0extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.04.002_bib3","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood.V122.21.1896.1896","article-title":"High prevalence of extramedullary relapse in patients with multiple myeloma treated with novel biological agents","volume":"122","author":"Mangiacavalli","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.002_bib4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-012-1414-5","article-title":"Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases","volume":"91","author":"Rasche","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2014.04.002_bib5","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blade","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.002_bib6","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1200\/JCO.2012.44.8845","article-title":"Multiple myeloma mimicking metastatic pancreas cancer","volume":"31","author":"Sher","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.002_bib7","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.04.002_bib8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.clml.2013.11.008","article-title":"Multiple myeloma and second malignancies","volume":"14","author":"Engelhardt","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2014.04.002_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.clml.2013.10.006","article-title":"Multiple myeloma and other malignancies: a pilot\u00a0study from the Houston VA","volume":"14","author":"Munker","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2014.04.002_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.1067","article-title":"Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma","volume":"67","author":"Oshima","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.04.002_bib11","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3816\/CLM.2007.n.039","article-title":"Liver involvement in multiple myeloma","volume":"7","author":"Bhandari","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2014.04.002_bib12","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1200\/JCO.2011.41.1413","article-title":"Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethazones","volume":"30","author":"Saboo","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.002_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ajh.2830200105","article-title":"Liver Involvement in multiple myeloma","volume":"20","author":"Perez-Soler","year":"1985","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.04.002_bib14","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3748\/wjg.15.1014","article-title":"Nodular liver lesions involving multiple myeloma: a case report and literature review","volume":"15","author":"Wu","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clml.2014.04.002_bib15","first-page":"81","article-title":"Non-secretory multiple myeloma relapsing as extramedullary liver plasmacytomas","volume":"20","author":"Lopes da Silva","year":"2011","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1016\/j.clml.2014.04.002_bib16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.SMJ.0000152542.36111.6F","article-title":"Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide","volume":"98","author":"del Giglio","year":"2005","journal-title":"South Med J"},{"key":"10.1016\/j.clml.2014.04.002_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0609.2009.01399.x","article-title":"P53 deletion may drive the clinical evolution and treatment response in multiple myeloma","volume":"84","author":"Lopez-Anglada","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.04.002_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjh.12223","article-title":"Cytogenetics of extramedullary manifestations in multiple myeloma","volume":"161","author":"Billecke","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.04.002_bib19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2141.2007.06649.x","article-title":"Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous p53 deletion and poor survival for multiple myeloma","volume":"138","author":"Chang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.04.002_bib20","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.leukres.2009.01.010","article-title":"p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma","volume":"33","author":"Sheth","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2014.04.002_bib21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.leukres.2007.09.013","article-title":"Efficacy of bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas","volume":"32","author":"Varettoni","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2014.04.002_bib22","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2169\/internalmedicine.48.2142","article-title":"Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomaide and dexamethasone","volume":"48","author":"Nakazato","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.clml.2014.04.002_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clml.2012.08.005","article-title":"Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases","volume":"13","author":"Ito","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2014.04.002_bib24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel agent therapy, ant the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:08Z","timestamp":1761870368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014001323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S2152265014001323"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.04.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic Extramedullary Disease in Multiple Myeloma With 17p Deletion","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}